{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:30:40Z","timestamp":1791325840828,"version":"4.3.1"},"reference-count":97,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chronic graft-versus-host disease (cGVHD) significantly contributes to late mortality after allogeneic stem cell transplantation, with bronchiolitis obliterans syndrome (BOS) being a particularly lethal and treatment-resistant complication despite available therapies. Bromodomain and extraterminal (BET) proteins are epigenetic readers driving inflammatory transcriptional programs across multiple cell types. We hypothesized that BET inhibition would suppress inflammatory T and B cells and decrease macrophage polarization to a profibrotic phenotype, alleviating disease. In an established BOS cGVHD model, BET inhibition reduced germinal center (GC) formation and responses through a reduction of the CXCL13:CXCR5 axis and inflammatory T follicular helper\/GC B cells in the spleen, along with a reduction in plasma cell infiltration within the lung. Mice with cGVHD had elevated pathogenic immunoglobulin G1 (IgG1) and IgM levels, both in circulation and deposited on lung tissue, which were attenuated under BET inhibition. Single-cell RNA-sequencing analysis revealed distinct cell states in the BOS lung vs control. In cGVHD mice, gene set enrichment analysis revealed the upregulation of profibrotic Arginase1 and Tgfb1 expression in alveolar macrophages (AM) and interstitial macrophages (IM), which was significantly reduced with BET inhibition. Furthermore, BET inhibition targeted lung-infiltrating M2 macrophages through the selective depletion of CD206+Fc\u03b3R+ IM and AM, ultimately resulting in reduced collagen deposition and improved lung function. Our findings reveal a previously unrecognized mechanistic axis of BET regulation during cGVHD fibrosis and highlight BET inhibition as a promising therapeutic strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031983","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:58:56Z","timestamp":1772477936000},"page":"2828-2844","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["BET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4693-8319","authenticated-orcid":false,"given":"Rathan","family":"Kumar","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"},{"name":"2Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotus","family":"Neidemire-Colley","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"},{"name":"2Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7292-4347","authenticated-orcid":false,"given":"Elizabeth A. R.","family":"Garfinkle","sequence":"additional","affiliation":[{"name":"3Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camryn","family":"Steere","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Surana","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Murray","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Giordano","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Martin","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson D.","family":"Woodbury","sequence":"additional","affiliation":[{"name":"4Division of Cardiac Surgery, Department of Surgery, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3366-5670","authenticated-orcid":false,"given":"Adithe","family":"Rivaldi","sequence":"additional","affiliation":[{"name":"3Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9957-9566","authenticated-orcid":false,"given":"Satishkumar","family":"Singh","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Corps","sequence":"additional","affiliation":[{"name":"5Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katlyn","family":"Lederer","sequence":"additional","affiliation":[{"name":"6Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malith","family":"Karunasiri","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7561-6481","authenticated-orcid":false,"given":"Matthew W.","family":"Gorr","sequence":"additional","affiliation":[{"name":"4Division of Cardiac Surgery, Department of Surgery, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8155-0204","authenticated-orcid":false,"given":"Loren E.","family":"Wold","sequence":"additional","affiliation":[{"name":"4Division of Cardiac Surgery, Department of Surgery, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-5427","authenticated-orcid":false,"given":"Lalit","family":"Sehgal","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Oestreich","sequence":"additional","affiliation":[{"name":"7Department of Microbial Infection and Immunity, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH"},{"name":"8Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"Grieselhuber","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"},{"name":"8Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-4522","authenticated-orcid":false,"given":"Marcos J.","family":"de Lima","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9608-9841","authenticated-orcid":false,"given":"Bruce R.","family":"Blazar","sequence":"additional","affiliation":[{"name":"9Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Department of Pediatrics, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1312-6748","authenticated-orcid":false,"given":"Ivan","family":"Maillard","sequence":"additional","affiliation":[{"name":"6Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"},{"name":"10Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Miller","sequence":"additional","affiliation":[{"name":"3Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children\u2019s Hospital, Columbus, OH"},{"name":"11Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah K.","family":"Choe","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"},{"name":"8Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4963-3629","authenticated-orcid":false,"given":"Parvathi","family":"Ranganathan","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"},{"name":"8Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2026060411214137600_bib1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/hematology.2021000301","article-title":"Updates in chronic graft-versus-host disease","volume":"2021","author":"Hamilton","year":"2021","journal-title":"Hematology (United States)"},{"issue":"8","key":"2026060411214137600_bib2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy - a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2026060411214137600_bib3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrclinonc.2014.102","article-title":"Current and emerging strategies for the prevention of graft-versus-host disease","volume":"11","author":"Choi","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2026060411214137600_bib4","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-01-514786","article-title":"Acute graft-versus-host disease: a bench-to-bedside update","volume":"124","author":"Holtan","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2026060411214137600_bib5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ajh.25355","article-title":"Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission","volume":"94","author":"Poir\u00e9","year":"2019","journal-title":"Am J Hematol"},{"key":"2026060411214137600_bib6","article-title":"Graft-versus-host disease","author":"James","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"2026060411214137600_bib7","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.bbmt.2016.01.012","article-title":"Comparing outcomes with bone marrow or peripheral blood stem cells as graft source for matched sibling transplants in severe aplastic anemia across different economic regions","volume":"22","author":"Kumar","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"2026060411214137600_bib8","first-page":"504.e1","article-title":"Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US claims analysis","volume":"27","author":"Bachier","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"2026060411214137600_bib9","doi-asserted-by":"crossref","first-page":"578314","DOI":"10.3389\/fimmu.2020.578314","article-title":"New approaches for the treatment of chronic graft-versus-host disease: current status and future directions","volume":"11","author":"Saidu","year":"2020","journal-title":"Front Immunol"},{"issue":"20","key":"2026060411214137600_bib10","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"issue":"13","key":"2026060411214137600_bib11","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood.2023022735","article-title":"Chronic graft-versus-host disease: unresolved complication or ancient history?","volume":"144","author":"Pidala","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026060411214137600_bib12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbmt.2013.11.025","article-title":"Pulmonary symptoms measured by the National Institutes of Health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease","volume":"20","author":"Palmer","year":"2014","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2026060411214137600_bib13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood-2016-08-693507","article-title":"How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation","volume":"129","author":"Williams","year":"2017","journal-title":"Blood"},{"issue":"1 suppl","key":"2026060411214137600_bib14","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.bbmt.2009.11.002","article-title":"Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation\u2014an increasingly recognized manifestation of chronic graft-versus-host disease","volume":"16","author":"Chien","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"2026060411214137600_bib15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2016-05-715896","article-title":"Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner","volume":"128","author":"McDonald-Hyman","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2026060411214137600_bib16","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1182\/blood-2004-10-3869","article-title":"Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM)","volume":"105","author":"Taylor","year":"2005","journal-title":"Blood"},{"issue":"25","key":"2026060411214137600_bib17","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2014-03-562231","article-title":"Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans","volume":"123","author":"Flynn","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2026060411214137600_bib18","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2011-07-364414","article-title":"Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans","volume":"119","author":"Srinivasan","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2026060411214137600_bib19","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood.2021014557","article-title":"BET-bromodomain and EZH2 inhibitor\u2013treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes","volume":"139","author":"Zaiken","year":"2022","journal-title":"Blood"},{"issue":"18","key":"2026060411214137600_bib20","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2017-01-758854","article-title":"Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-\u03b2 production","volume":"129","author":"Du","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2026060411214137600_bib21","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood.2024025036","article-title":"Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD","volume":"145","author":"Zaiken","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026060411214137600_bib22","doi-asserted-by":"crossref","first-page":"e135468","DOI":"10.1172\/JCI135468","article-title":"Tissue-resident PSGL1loCD4+T cells promote B cell differentiation and chronic graft-versus-host disease-associated autoimmunity","volume":"131","author":"Kong","year":"2021","journal-title":"J Clin Invest"},{"issue":"25","key":"2026060411214137600_bib23","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/blood.2022016581","article-title":"Trafficking between clonally related peripheral T-helper cells and tissue-resident T-helper cells in chronic GVHD","volume":"140","author":"Kong","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2026060411214137600_bib24","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1182\/blood-2005-01-0062","article-title":"TGF-\u03b2 in allogeneic stem cell transplantation: friend or foe?","volume":"106","author":"Banovic","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2026060411214137600_bib25","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.4049\/jimmunol.163.10.5693","article-title":"Anti-TGF-\u03b2 treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma","volume":"163","author":"McCormick","year":"1999","journal-title":"The J Immunol"},{"issue":"26","key":"2026060411214137600_bib26","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2026060411214137600_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","volume":"129","author":"MacDonald","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2026060411214137600_bib28","first-page":"S244","article-title":"Single Cell RNA sequencing identifies IL-17- and CSF-1-associated pathologic gene expression signatures in blood during chronic graft-versus-host disease","volume":"29","author":"Boiko","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"18","key":"2026060411214137600_bib29","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3390\/cells13181524","article-title":"Current approaches for the prevention and treatment of acute and chronic GVHD","volume":"13","author":"Olivieri","year":"2024","journal-title":"Cells"},{"issue":"8","key":"2026060411214137600_bib30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood.2024026633","article-title":"FDA-approved therapies for chronic GVHD","volume":"145","author":"Lee","year":"2025","journal-title":"Blood"},{"issue":"21","key":"2026060411214137600_bib31","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2026060411214137600_bib32","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study","volume":"41","author":"Miklos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026060411214137600_bib33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2020-139445","article-title":"Belumosudil for chronic graft-versus-host disease (cGVHD) after 2 or more prior lines of therapy: the Rockstar Study (KD025-213) [abstract]","volume":"136","author":"Cutler","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2026060411214137600_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026060411214137600_bib35","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2023-179365","article-title":"A phase II multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation [abstract]","volume":"142","author":"DeFilipp","year":"2023","journal-title":"Blood"},{"issue":"24","key":"2026060411214137600_bib36","doi-asserted-by":"crossref","first-page":"6263","DOI":"10.1182\/bloodadvances.2022008095","article-title":"Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials","volume":"6","author":"DeFilipp","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2026060411214137600_bib37","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1172\/JCI75935","article-title":"CSF-1-dependent donor-derived macrophages mediate chronic graft-versus-host disease","volume":"124","author":"Alexander","year":"2014","journal-title":"J Clin Invest"},{"issue":"10","key":"2026060411214137600_bib38","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.2023022040","article-title":"CSF1R inhibition promotes neuroinflammation and behavioral deficits during graft-versus-host disease in mice","volume":"143","author":"Adams","year":"2024","journal-title":"Blood"},{"issue":"19","key":"2026060411214137600_bib39","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1182\/blood-2010-02-266296","article-title":"An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation","volume":"116","author":"MacDonald","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2026060411214137600_bib40","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1056\/NEJMe2407731","article-title":"Targeting CSF1R in chronic GVHD \u2014 lessons in translation","volume":"391","author":"Mohty","year":"2024","journal-title":"New Engl J Med"},{"issue":"11","key":"2026060411214137600_bib41","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","article-title":"Axatilimab in recurrent or refractory chronic graft-versus-host disease","volume":"391","author":"Wolff","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"2026060411214137600_bib42","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study","volume":"41","author":"Kitko","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026060411214137600_bib43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/cells14040238","article-title":"Treatment response in individual organs affected by chronic graft-versus-host disease","volume":"14","author":"Morishita","year":"2025","journal-title":"Cells"},{"issue":"3","key":"2026060411214137600_bib44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/2040620715576662","article-title":"Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence","volume":"6","author":"Chaidos","year":"2015","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"2026060411214137600_bib45","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Lov\u00e9n","year":"2013","journal-title":"Cell"},{"key":"2026060411214137600_bib46","doi-asserted-by":"crossref","first-page":"728777","DOI":"10.3389\/fmolb.2021.728777","article-title":"The functions of BET proteins in gene transcription of biology and diseases","volume":"8","author":"Cheung","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"11","key":"2026060411214137600_bib47","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.1093\/nar\/gkx212","article-title":"Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4-and MYC-dependent manner","volume":"45","author":"Mishra","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2026060411214137600_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/2159-8290.CD-17-0605","article-title":"BET proteins as targets for anticancer treatment","volume":"8","author":"Stathis","year":"2018","journal-title":"Cancer Discov"},{"issue":"8","key":"2026060411214137600_bib49","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: a novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"2026060411214137600_bib50","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"issue":"suppl 1","key":"2026060411214137600_bib51","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1182\/blood-2018-99-117089","article-title":"A phase I study of molibresib (GSK525762), a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I\/II open label single agent study in subjects with non-Hodgkin\u2019s lymphoma (NHL)","volume":"132","author":"Dickinson","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2026060411214137600_bib52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1078-0432.CCR-22-1284","article-title":"A phase I\/II open-label study of molibresib for the treatment of relapsed\/refractory hematologic malignancies","volume":"29","author":"Dawson","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2026060411214137600_bib53","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41416-019-0724-y","article-title":"Targeting BRD\/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF\/MEK inhibitors in melanoma","volume":"122","author":"Tiago","year":"2020","journal-title":"Br J Cancer"},{"issue":"4","key":"2026060411214137600_bib54","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/2159-8290.CD-17-0902","article-title":"BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor","volume":"8","author":"Ozer","year":"2018","journal-title":"Cancer Discov"},{"issue":"23","key":"2026060411214137600_bib55","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.589.589","article-title":"Genome-wide mapping reveals BRD4 in regulation of tumor-driver genes in cutaneous T-cell lymphoma","volume":"126","author":"Mishra","year":"2015","journal-title":"Blood"},{"key":"2026060411214137600_bib56","doi-asserted-by":"crossref","first-page":"S403","DOI":"10.1016\/S2152-2650(23)01258-2","article-title":"MPN-559 bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients with relapsed or refractory myelofibrosis (R\/R MF) and other advanced myeloid neoplasms: a phase I study","volume":"23","author":"Watts","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2026060411214137600_bib57","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1182\/blood-2024-205105","article-title":"Interim analysis of promise, a clinical study combining the BET inhibitor OPN-2853 with ruxolitinib in patients with advanced myelofibrosis experiencing an inadequate response to ruxolitinib","volume":"144","author":"Mead","year":"2024","journal-title":"Blood"},{"issue":"7327","key":"2026060411214137600_bib58","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme","year":"2010","journal-title":"Nature"},{"key":"2026060411214137600_bib59","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.3389\/fimmu.2018.03104","article-title":"BET bromodomain inhibitors which permit Treg function enable a combinatorial strategy to suppress GVHD in pre-clinical allogeneic HSCT","volume":"10","author":"Copsel","year":"2019","journal-title":"Front Immunol"},{"issue":"17","key":"2026060411214137600_bib60","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/blood-2014-08-598037","article-title":"BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in Mice","volume":"125","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"2026060411214137600_bib61","article-title":"Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes","volume":"103(2):427-436","author":"Li","year":"2020","journal-title":"Biology of Reproduction"},{"issue":"1","key":"2026060411214137600_bib62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/1078-0432.CCR-13-3346","article-title":"Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma","volume":"21","author":"Trabucco","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2026060411214137600_bib63","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cell.2012.06.045","article-title":"Small-molecule inhibition of BRDT for male contraception","volume":"150","author":"Matzuk","year":"2012","journal-title":"Cell"},{"issue":"7327","key":"2026060411214137600_bib64","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"2026060411214137600_bib65","doi-asserted-by":"crossref","first-page":"760789","DOI":"10.3389\/fonc.2021.760789","article-title":"Inhibition of bromodomain and extra terminal (BET) domain activity modulates the IL-23R\/IL-17 axis and suppresses acute graft-versus-host disease","volume":"11","author":"Snyder","year":"2021","journal-title":"Front Oncol"},{"key":"2026060411214137600_bib66","first-page":"232870","article-title":"Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer","volume":"2014","author":"Chen","year":"2014","journal-title":"Biomed Res Int"},{"issue":"3","key":"2026060411214137600_bib67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/imm.12648","article-title":"T follicular helper cell programming by cytokine-mediated events","volume":"149","author":"Read","year":"2016","journal-title":"Immunology"},{"issue":"JUN","key":"2026060411214137600_bib68","first-page":"296","article-title":"CXCR5, the defining marker for follicular B helper T (TFH) cells","volume":"6","author":"Moser","year":"2015","journal-title":"Front Immunol"},{"issue":"17","key":"2026060411214137600_bib69","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.3390\/cells11172649","article-title":"The CXCL13\/CXCR5 immune axis in health and disease\u2014implications for intrathecal B cell activities in neuroinflammation","volume":"11","author":"Harrer","year":"2022","journal-title":"Cells"},{"issue":"1","key":"2026060411214137600_bib70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/JLB.3RU0720-418R","article-title":"Alveolar and lung interstitial macrophages: definitions, functions, and roles in lung fibrosis","volume":"110","author":"Shi","year":"2021","journal-title":"J Leukoc Biol"},{"issue":"4","key":"2026060411214137600_bib71","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1165\/rcmb.2013-0086MA","article-title":"Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung","volume":"49","author":"Misharin","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"2026060411214137600_bib72","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/019021490944232","article-title":"Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology","volume":"31","author":"Chakrabarti","year":"2005","journal-title":"Exp Lung Res"},{"issue":"2","key":"2026060411214137600_bib73","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1101\/gad.14.2.163","article-title":"Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-\u03b2 and promotes tumor invasion and angiogenesis","volume":"14","author":"Yu","year":"2000","journal-title":"Genes Dev"},{"issue":"8","key":"2026060411214137600_bib74","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1161\/CIRCRESAHA.114.302653","article-title":"Cardiomyocyte-specific transforming growth factor \u03b2 suppression blocks neutrophil infiltration, augments multiple cytoprotective cascades, and reduces early mortality after myocardial infarction","volume":"114","author":"Rainer","year":"2014","journal-title":"Circ Res"},{"issue":"22","key":"2026060411214137600_bib75","doi-asserted-by":"crossref","first-page":"13763","DOI":"10.1074\/jbc.M114.622274","article-title":"Recruitment of matrix metalloproteinase-9 (MMP-9) to the fibroblast cell surface by lysyl hydroxylase 3 (LH3) triggers transforming growth factor-\u03b2 (TGF-\u03b2) activation and fibroblast differentiation","volume":"290","author":"Dayer","year":"2015","journal-title":"J Biol Chem"},{"issue":"7","key":"2026060411214137600_bib76","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1172\/JCI90593","article-title":"Cytokine mediators of chronic graft-versus-host disease","volume":"127","author":"MacDonald","year":"2017","journal-title":"J Clin Invest"},{"issue":"6","key":"2026060411214137600_bib77","first-page":"452","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2020 Etiology and Prevention Working Group Report","volume":"27","author":"Williams","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"9","key":"2026060411214137600_bib78","doi-asserted-by":"crossref","first-page":"678.e1","DOI":"10.1016\/j.jtct.2025.05.016","article-title":"NIH Chronic Graft-Versus-Host Disease Consensus Conference 2025 update","volume":"31","author":"Lee","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2026060411214137600_bib79","first-page":"545","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report","volume":"27","author":"Kitko","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2026060411214137600_bib80","first-page":"515","article-title":"Defining airflow obstruction","volume":"3","author":"Eschenbacher","year":"2016","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"1","key":"2026060411214137600_bib81","doi-asserted-by":"crossref","first-page":"2045894020912937","DOI":"10.1177\/2045894020912937","article-title":"Optimization of combined measures of airway physiology and cardiovascular hemodynamics in mice","volume":"10","author":"Kopf","year":"2020","journal-title":"Pulm Circ"},{"issue":"1","key":"2026060411214137600_bib82","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12931-019-1177-9","article-title":"Determination of reliable lung function parameters in intubated mice","volume":"20","author":"Bonnardel","year":"2019","journal-title":"Respir Res"},{"issue":"1","key":"2026060411214137600_bib83","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12931-025-03306-6","article-title":"An orally bioavailable BRD4 inhibitor disrupts expansion of a pathogenic epithelial-mesenchymal niche in bleomycin-induced fibrosis","volume":"26","author":"Skibba","year":"2025","journal-title":"Respir Res"},{"issue":"10","key":"2026060411214137600_bib84","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.176596","article-title":"Shared roles of immune and stromal cells in the pathogenesis of human bronchiolitis obliterans syndrome","volume":"10","author":"Mellors","year":"2025","journal-title":"JCI Insight"},{"issue":"8","key":"2026060411214137600_bib85","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1073\/pnas.1222900110","article-title":"H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease","volume":"110","author":"Sahaf","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"2026060411214137600_bib86","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1182\/blood-2014-11-613323","article-title":"Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans","volume":"125","author":"Nakasone","year":"2015","journal-title":"Blood"},{"issue":"26","key":"2026060411214137600_bib87","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1182\/blood.2024027301","article-title":"Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD","volume":"145","author":"Habenicht","year":"2025","journal-title":"Blood"},{"issue":"15","key":"2026060411214137600_bib88","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1042\/CS20220531","article-title":"M1\/M2 macrophages and their overlaps - myth or reality?","volume":"137","author":"Strizova","year":"2023","journal-title":"Clin Sci"},{"issue":"19","key":"2026060411214137600_bib89","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/blood.2024025337","article-title":"Defining pathogenic IL-17 and CSF-1 gene expression signatures in chronic graft-versus-host disease","volume":"145","author":"Boiko","year":"2025","journal-title":"Blood"},{"issue":"10","key":"2026060411214137600_bib90","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"issue":"6","key":"2026060411214137600_bib91","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1055\/s-0037-1613331","article-title":"Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor","volume":"88","author":"Hansen","year":"2002","journal-title":"Thromb Haemost"},{"key":"2026060411214137600_bib92","doi-asserted-by":"crossref","first-page":"728322","DOI":"10.3389\/fimmu.2021.728322","article-title":"The dual targeting of FcRn and Fc\u03b3Rs via monomeric Fc fragments results in strong inhibition of IgG-dependent autoimmune pathologies","volume":"12","author":"Monnet","year":"2021","journal-title":"Front Immunol"},{"key":"2026060411214137600_bib93","doi-asserted-by":"crossref","first-page":"1229112","DOI":"10.3389\/fneur.2023.1229112","article-title":"FcRn receptor antagonists in the management of myasthenia gravis","volume":"14","author":"Bhandari","year":"2023","journal-title":"Front Neurol"},{"issue":"5","key":"2026060411214137600_bib94","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/leu.2014.332","article-title":"Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years","volume":"29","author":"Cornelissen","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"2026060411214137600_bib95","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2026060411214137600_bib96","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41409-018-0171-z","article-title":"Epidemiology and biology of relapse after stem cell transplantation","volume":"53","author":"Horowitz","year":"2018","journal-title":"Bone Marrow Transpl"},{"key":"2026060411214137600_bib97","doi-asserted-by":"crossref","first-page":"812207","DOI":"10.3389\/fonc.2021.812207","article-title":"Treatment of AML relapse after Allo-HCT","volume":"11","author":"Webster","year":"2021","journal-title":"Front Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/23\/2828\/2524477\/blood_bld-2025-031983-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/23\/2828\/2524477\/blood_bld-2025-031983-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:22:00Z","timestamp":1780586520000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/23\/2828\/566894\/BET-inhibition-blunts-antibody-production-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":97,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031983","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,4]]},"published":{"date-parts":[[2026,6,4]]}}}